Topic Listing for ARYX THERAPEUTICS INC

Accounting Other Terms Accounting Tax Considerations
Accredited Investor Accredited Investor Status
Acknowledgement Regarding Investors Acquisition Securities Actions Pending
Additional Covenants Additional Indication Lack Drug Accumulation
Affiliate Also Provides Update Product Partnering Efforts
Amendment Amendment Prior Agreement
Amendment Procter Gamble License Development Commercialization Agreement Amendment Restatement Certificate Incorporation
Amendments Writing Integration Amiodarone Background
Annual Meeting Stockholders Held 2009 Annual Review Benchmarking Executive Compensation
Anti-arrhythmic Agent Anti-kickback False Claims Laws Prescription Drug Marketing Act
Anti-takeover Provisions Charter Documents Delaware Law Make Acquisition Antiarrhythmic Agent
Anticoagulant Agent Appendix
Application Internal Revenue Code 409a Application Payments Proceeds
Application Takeover Protections Ary Therapeutics Inc
Aryx Therapeutics Aryx Therapeutics Aligns Operations Development Activities
Aryx Therapeutics Inc Aryx Therapeutics Reports 2009 Results
Aryx Therapeutics Reports Full 2007 Financial Results Assignment
Ati-2042 Ati-5923
Ati-5923-an Oral Anticoagulant Agent Ati-7505
Ati-7505-a Prokinetic Agent Treatment Gastrointestinal Disorders Ati-9242
Ati-9242-an Agent Treatment Schizophrenia Atrial Fibrillation
Attachment Audit Committee
Authorization Enforcement Authorization Financing Statements
Authorization Power Authorized Signatures Completed Vote Counted Date Sign Below
Available Information Basic Rate
Basis Presentation Because Number Product Candidates Considering Variety Target Indications
Because Small Number Existing Stockholders Own Large Percentage Beneficial Owner Shares Registered Name Broker Bank
Better After-tax Biological Hazardous Materials Manner Causes Contamination Injury Violates
Borrowers Books Borrowing Resolutions
Budiodarone Budiodarone-antiarrhythmic Agent Treatment Atrial Fibrillation
Business Capitalization
Cash Bonus Plan Payment Targets Named Executive Officers Cash Compensation Arrangements
Cash Equivalents Cash Incentive Payments Bonuses 2008 Salaries Named Executive
Certain Fees Certain Limitations
Certain Relationships Related Transactions Director Independence Certificate Adjustment
Certification Change Accounting Estimates
Change Control Change Control Termination
Change Vote After Submitting Proxy Changes Business Management Ownership Locations
Changes Internal Control Over Financial Reporting Choice Law Venue
Choice Law Venue Jury Trial Waiver Cisapride Background
Clinical Development Status Clinical Statistical Significance Demonstrated Primary Endpoint
Code Code Conduct
Collaboration Procter Gamble Pharmaceuticals Collaborative Arrangements Not Currently Exist Product Candidates Establish
Collateral Collateral Schedule
Commercial Success Products Develop Depend Degree Market Acceptance Common Stock
Common Stock Purchase Agreement Common Stock Purchase Agreement Certificate Closing
Common Stock Purchase Agreement Compliance Certificate Common Stock Purchase Agreement Form Fixed Request Notice
Comparison Cumulative Total Return Compensation Actions Executive Officers
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Committee Report Competition
Competitors Able Develop Market Products Effective Safer Less Compliance
Compliance Certificate Compliance Law
Compliance Laws Comprehensive Income Loss
Comprehensive Loss Conclusion
Conditions Precedent Credit Extension Conditions Precedent Effectiveness Amendment
Conference Call Conference Call Webcast Information
Confidentiality Conflicts
Contact Contingent Obligation
Contractual Obligations Controls Procedures
Corporate Existence Corporate Governance Guidelines
Corporate Individual Performance Goals Named Executive Officers Cost Collaboration Service Revenue
Cost Collaboration Services Costs Associated Exit Disposal Activities
Counterparts Covenant Default
Covenant Deliver Creation Direct Financial Obligation Off-balance Sheet Arrangement
Credit Extension Critical Accounting Policies Significant Estimates
Critical Accounting Policies Significant Judgments Estimates Cumulative Effect Change Accounting Principle
David Beier Debt Financing
Debt Restructure Default
Deferred Offering Costs Definition Cause
Definition Good Reason Definitions
Delaware Delivery Registration Statement Prospectus Subsequent Changes
Demand Waiver Departure Directors Certain Officers Election Appointment Compensatory
Deposit Securities Accounts Dilutive Effect
Director Compensation Table Directors Executive Officers Corporate Governance
Disclosure Disclosure Schedule Relating Common Stock Purchase Agreement Dated
Dispositions Dividend Policy
Documents Financial Statements Documents Incorporated Reference
Due Organization Authorization Power Authority Efficacy Tecarfarin Mirrors Earlier Studies While Primary Endpoint
Electronic Delivery Future Stockholder Communications Eligible Equipment
Embraceac Results Employee Stock Purchase Plan
Employees Employment Agreements
Encumbrance Entire Agreement Modification
Entry Material Definitive Agreement Environmental Compliance
Equipment Equipment Advance
Equipment Line Equipment Maturity Date
Equity Compensation Plan Information Equity Financing
Equity Financing Facility Equity Incentive Plan
Erisa Estimates
Evaluation Disclosure Controls Procedures Events Default
Exclusive Patent License Agreement University Toledo Executive Compensation
Executive Employment Agreements Executive Officers Registrant
Executives Resignation Good Reason Exemption Registration Valid Issuances
Exhibits Expenses Accrued Contractual Arrangements Parties
Expiration Date Automatic Exercise Explanatory
Fail Attract Keep Senior Management Key Scientific Personnel Fail Continue Comply Listing Requirements Nasdaq Global Market
Failure Adequately Protect Trade Secrets Other Intellectual Property Failure Delay Commencing Completing Clinical Trials Product Candidates
Failure Deliver Shares Fair Value Estimates Auction Rate Securities
Fair Value Financial Instruments Fda Approval Process
Fees Final Payment
Financed Equipment Financial Results
Financial Risk Financial Statements Exhibits
Financial Statements Reports Certificates Financial Statements Supplementary Data
Find Out Results Voting Annual Meeting Fixed Request Terms
Fluctuations Operating Results Cause Stock Price Decline Food Drug Administration Amendments Act 2007
Foreign Currency Risk Form 10-k
Form 10-q Form Notice Effectiveness Registration Statement
Form Warrant Forward Looking Statement
Forward-looking Statement Forward-looking Statements
Fractional Shares Freestanding Warrants Cumulative Effect Change Accounting Principle
Fremont 2008 Fremont 2009
Fremont California 2007 Full Disclosure
Fundamental Transaction Funding Date
Further Assurances Future Sales Common Stock Public Market Cause Price
Gaap General Administrative
General Electric Commercial Finance General Solicitation
General Solicitation Advertising Global Credit Financial Market Conditions Negatively Impact Value
Governing Law Government Compliance
Governmental Approval Governmental Authority
Governmental Review Grant Security Interest
Hatch-waxman Act Headings
Held 2009 Herm Rosenman
Highlights Historic Warfarin Usage
Impairment Long-lived Assets Important Notice Regarding Availability Proxy Materials Stockholder Meeting
Income Taxes Incurred Significant Operating Losses Since Inception Expect Continue
Indebtedness Indebtedness Solvency
Indemnification Indemnification Agreements Executive Officers Directors
Indemnifications Independence Aryx Therapeutics Board Directors
Independence Board Directors Independent Registered Public Accounting Firm Fees Services
Index Indications Market Opportunity
Information Information Regarding Committees Board Directors
Initial Public Offering Insolvency
Insolvency Proceeding Instrument Adherence
Insurance Integrated Offering
Integration Clause Interest
Interest Expense Interest Other Income Net
Interest Rate Market Risk Interest Rate Risk
Interim Payments Investment Act Status
Investment Purpose Investor Rights Agreement
Issuance Issuance Securities
Judgments Keeping Records Books Account Foreign Corrupt Practices Act
Keith Leonard Lars Ekman Phd
Lead Independent Director Legal Proceedings
Lender Lenders Expenses
Liability Collateral License Development Commercialization Agreement
Lien Lighthouse Capital Partners
Limitations Currently Marketed Antipsychotics Limitations Effectiveness Controls
Limitations Holdings Issuances Listing Maintenance Requirements
Litigation Litigation Cooperation
Loan Documents Loan Security Agreement
Make Difficult Costly Raise Additional Capital Managements Report Internal Control Over Financial Reporting 2007
Managements Report Internal Control Over Financial Reporting 2008 Mandatory Prepayment Acceleration
Manipulation Price Manufacturing
Market Common Stock Market Registrants Common Equity Related Stockholder Matters Issuer
Marketable Securities Material Adverse Change
Material Adverse Effect Material Agreements
Material Deviation Financial Statements Meetings Board Directors
Members Board Directors Mergers Acquisitions
Mergers Reclassifications Miscellaneous
Misrepresentations Modified Gross-up
Montreux Equity Partners Sbic Mpm Bioventures Strategic Fund
Need Hire Additional Employees Order Commercialize Product Candidates Need Implement Additional Finance Accounting Systems Procedures Controls
Need Raise Additional Capital Need Substantial Additional Funding Unable Raise Capital Needed
Negative Covenants Net Issue Election
Net Issue Election Notice Net Loss Per Share
Nicholas Simon Nominating Corporate Governance Committee
Non-employee Directors Stock Option Plan Nonqualified Deferred Compensation
Not Able Obtain Required Regulatory Approvals Commercialize Product Not Applicable
Not Successful Efforts Identify Discover Additional Candidates Using Not Voted Via Internet Telephone Fold Along Perforation
Notes Condensed Consolidated Financial Statements Notes Consolidated Financial Statements
Notice Annual Meeting Stockholders Held 2008 Notices
Notices Litigation Default Now Therefore
Number 001-33782 Obligations
Off-balance Sheet Arrangements Operating Documents
Operating Leases Operation Business
Option Exercises Stock Vested 2007 Option Exercises Stock Vested 2008
Oral Anti-coagulation Organization Good Standing Power
Organization Standing Investor Other Agreements
Other Agreements Alternate Transactions Other Equipment
Other Events Other Information
Other Regulatory Requirements Outstanding Equity Awards 2007
Overview Oxford Finance Corporation
Partial Exercise Participation Agreement
Parties Not Manufacture Product Candidates Sufficient Quantities Acceptable Patents Intellectual Property
Patient Population Study Patients Schizophrenia
Paul Goddard Phd Paul Sekhri
Paying Proxy Solicitation Payment Default
Payment Purchase Price Pediatric Information
Pension Benefits Performance Graph
Performance Measurement Comparison Periods Worsening Economic Conditions Difficult Costly Raise Additional
Permitted Investments Permitted Liens
Person Peter Milner
Physician Drug Samples Plan
Please Sign Reverse Side Return Immediately Post Closing Obligations Letter
Post-retirement Benefits Potential Market Commercialization Strategy
Power Attorney Pre-approval Policies Procedures
Preclinical Development Programs Preclinical Studies Not Produce Successful Results Clinical Trials
Preferred Stock Prepayment Fee
Principal Accountant Fees Services Principal Facility Located Near Known Earthquake Fault Zones
Principles Consolidation Private Issue
Private Placement Problems Toxicity Existing Drugs
Procedures Borrowing Proceeds
Proceeds Sale Registered Securities Product Candidates
Product Candidates Remain Subject Ongoing Regulatory Review Even Product Development Highlights
Product Liability Lawsuits Brought Against Incur Substantial Liabilities Prokinetic Agent
Properties Property Equipment
Protective Payments Provided However
Proxy Solicited Board Directors Annual Meeting Stockholders Held Proxy Statement Annual Report Stockholders Available Http Wwwenvisionreportscom
Purchasers Certificate Subsequent Sale Quantitative Qualitative Disclosures Market Risk
Quarterly Financial Data Ratification Selection Independent Registered Public Accounting Firm-the Board
Real Property Holding Corporation Receiving Materials
Recent Accounting Pronouncements Recent Accounting Updates
Recent Sales Unregistered Securities Recitals
Reclassification Registered Organization
Registration Listing Registration Rights Agreement
Regulatory Compliance Related Party Receivable
Related Party Transaction Related-person Transactions Policy Procedures
Release Reliance Exemptions
Rely Parties Conduct Clinical Trials Not Perform Contractually Remainder Page Left Intentionally Blank Signature Pages Follow
Repayment Report Audit Committee Board Directors
Representations Covenants Holder Representations Warranties Covenants
Representations Warranties Covenants Investor Required Obtain Alternate Third-party Manufacturers Delay Prevent Clinical
Requirement Law Resales Securities
Research Development Research Development Costs
Research Development Expense Reservation Common Stock
Reserved Shares Valid Issuance Responsible Officer
Restricted Cash Restructure
Restructure Warrant Results Operations
Results Operations Financial Condition Retrometabolic Drug Design
Revenue Revenue Collaboration Procter Gamble Pharmaceuticals
Revenue Recognition Reverse Stock Split
Rights Remedies Risks Relating Ownership Common Stock
Risks Uncertainties Robert Adelman
Role Compensation Committee Setting Executive Rule 144
Safety Issues Relating Product Candidates Original Drugs Been Salaries Named Executive Officers Cash Incentive Payments Bonuses
Sarbanes-oxley Act 2002 Schedule 14a
Scheduled Payments Schizophrenia
Scientific Advisory Board Secondary Endpoint Results
Secured Promissory Secured Promissory Provided Lender
Secured Promissory Record Securities Act
Securities Compliance Securities Exchange Act 1934
Security Ownership Certain Beneficial Owners Management Related Stockholder Security Priority
Sell Shares Common Stock Existing Committed Equity Line Selling General Administrative
Selling General Administrative Expense Severability
Severability Provisions Severance Benefits Good Reason Resignation
Severance Benefits Termination Without Cause Severance Change Control Arrangements
Shares Reserved Future Issuance Signature
Signature Page Follows Signatures
Significant Risks Uncertainties Solvency
Some Patents Expire Invalidated Unenforceable Patent Applications Not Statistical Significance Demonstrated Primary Endpoint
Statutory Underwriter Status Stock Option Award Grants Executive Officers Directors
Stock Option Awards Named Executive Officers Stock Options Granted Non-employees
Stock Price Extremely Volatile Investment Common Suffer Decline Stock Splits Dividends
Stock-based Compensation Stockholder Communications Board Directors
Stockholder Proposals Due Next Annual Meeting Stockholder Record Shares Registered Name
Stockholder Rights Stockholders Equity
Stockholders Equity Deficit Strategy
Study Design Study Design Analyses
Study Design Implementation Study Results
Submission Matters Vote Security Holders Subordinated Debt
Subscription Subsequent Event
Subsequent Events Subsidiaries
Subsidiaries Investments Subsidiary
Success Depends Substantially Most Advanced Product Candidates Still Successors Assigns
Summary Compensation Table Survival
Tax Returns Payments Pension Contributions Taxes
Taxes Pensions Tecarfarin
Tecarfarin-an Oral Anticoagulant Agent Termination Employment
Termination Material Definitive Agreement Termination Without Cause
Third-party Claims Intellectual Property Infringement Require Spend Significant Third-party Manufacturers Increase Risk Not Adequate Supplies Product
Time Essence Title Assets
Trading Price Common Stock Decline Due Risks Investors Transactions Affiliates
Trial Design Ubs Juniper Crossover Fund Llc
Unable Establish Sales Marketing Capabilities Enter Agreements Parties Understand Agree Completely Terms Set Forth Aryx Therapeutics
Undisclosed Events Circumstances Undisclosed Liabilities
University Toledo License Agreement Unregistered Sales Equity Securities
Unregistered Sales Equity Securities Proceeds Voluntary Prepayment
Vote Vote Annual Meeting
Votes Votes Counted
Votes Needed Approve Each Proposal Waiver Remedies Cumulative
Waivers Warfarin Background
Warrant Washout Data Secondary End Points Reinforce Top-line Efficacy
Washout Period Results What Another Matter Properly Brought Before Meeting
What Mean Receive Proxy Card What Mean Receive Set Proxy Materials
What Proxy Materials Available Internet What Quorum Requirement
What Return Proxy Card Not Make Specific Choices What Return Proxy Card Otherwise Vote Not Make
What Voting Whereas
Witness Whereof Workforce Reduction 2009 Future Expense Reductions Adverse Impact
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki